FILING ANALYSIS · WEDNESDAY, JULY 1
Ipsen Sa 0MH6 — RNS
positive
Ipsen's acquisition of Memo Therapeutics AG for up to €900m expands its rare disease portfolio with a first-in-class BK polyomavirus antibody, a significant addition given the promising Phase II trial results. The deal is expected to close in Q3 2026 and is already factored into Ipsen's current full-year guidance.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →